Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2019. The document serves as a transaction notification regarding a sale of ordinary shares by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a specific insider transaction.
| Transaction Detail | Value |
|---|---|
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Type | Sale |
| Volume | 3,000 shares |
| Price per Share | £17.514 |
| Transaction Date | October 30, 2019 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely discloses a reduction in the shareholding of Ms. S. Jackson, SVP, Global Communications & CEO Office.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory notification of a PDMR transaction.
Investor Verification Checklist
- Verify the total number of shares held by Ms. S. Jackson following this sale to assess remaining ownership stakes.
- Confirm the transaction price of £17.514 against the market price of GSK shares on October 30, 2019.
- Review the company's most recent Form 20-F or interim financial report for actual revenue, profit, and liquidity metrics, as they are absent here.